Large-scale production of recombinant adeno-associated virus (rAAV).
- Author:
Feng WANG
1
;
Yong DIAO
;
Weidong XIAO
;
Ruian XU
Author Information
1. Engineering Research Center of Molecular Medicine, Ministry of Education, Quanzhou 362021, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Biotechnology;
methods;
Dependovirus;
genetics;
metabolism;
physiology;
Genetic Therapy;
Genetic Vectors;
biosynthesis;
genetics;
Humans;
Insecta;
cytology;
Recombinant Proteins;
biosynthesis;
genetics;
Virus Assembly
- From:
Chinese Journal of Biotechnology
2009;25(11):1608-1613
- CountryChina
- Language:Chinese
-
Abstract:
Recombinant adeno-associated virus has been proven to be a promising gene delivery vector for human gene therapy with many advantages. Successful applications of recombinant adeno-associated virus vectors in preclinical and clinical human gene therapies make it become a demanded product. A well-established and large-scale production system is therefore required. Since wild type of adeno-associated virus was well characterized in 1989, progress has been made. Particularly, package system of recombinant adeno-associated virus has been developed to use insect cell instead of human cell. These advances in adeno-associated virus production will allow it to meet the demands of basic research and clinical applications. This review will focus on trends in packaging systems and development on a large scale of recombinant adeno-associated virus production.
